| 초록 |
Immunotherapy has been emerged as a next generation of anticancer therapy. However, immunotherapy agents including immune checkpoint inhibitor and CAR-T cell showed to have limited therapeutic effect for solid tumor due to the tumor microenvironment (TME). Herein, to overcome the limited therapeutic effect in solid tumors, polyethyleneimine (PEI)-based biocompatibility convertible immuno-sensitizer (BCI) was developed. BCI induces in situ tumor destruction through the biocompatibility conversion in response to tumor acidic pH conditions. Consequentially, tumor antigen release induced by BCI elicits the maturation of dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs) response leading powerful antitumor immune response. Antitumor immunity and tumor growth inhibition were confirmed through the in vivo experiments. These results may suggest alternative accesses to improve the immunotherapy as well as polymer-based immunotherapeutic agent platform. |
